Yuling Zhou
Changsha, 410013, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Untargeted metabolomics reveals compositional alterations in the muscle tissue of hybrid crucian carp.
Journal: Comparative biochemistry and physiology. Part D, Genomics & proteomics
Published: June 27, 2025
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 02, 2023
Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 27, 2022
Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 18, 2022
The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study.
Journal: Translational lung cancer research
Published: January 17, 2022
Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report.
Journal: Annals of translational medicine
Published: November 04, 2020
Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
Journal: JAMA network open
Published: March 20, 2020
Concurrent ERBB2 missense mutations D769Y and D742 N Are Novel Acquired Mechanism of Gefitinib Resistance but Responds to Gefitinib plus Pyrotinib.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 19, 2020
Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation-Mediated Erlotinib Resistance After Failure of Chemotherapy.
Journal: JTO clinical and research reports
Published: January 28, 2020
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 12, 2020
Showing 1-12 of 12
Last Updated: 09/26/2026